• 대한한방내과학회지
• /
• 제40권6호
• /
• pp.1122-1135
• /
• 2019

Purpose: The purpose of this study was to conduct a clinical analysis of patients treated for dizziness with Jeoreongchajeonja-tang, evaluate the effect of Jeoreongchajeonja-tang administration, and present indications of Jeoreongchajeonja-tang in dizziness. Methods: A retrospective study was conducted on 63 patients who were admitted to the Oriental Hospital of Se-Myung University from August 2012 to June 2019, complaining of dizziness, so who took Jeoreongchajeonja-tang. Results: 1) As a result of the analysis of the general characteristics of patients who took Jeoreongchajeonja-tang with dizziness, women were 2.7 times more than men. The age distribution was: patients in their 70s, 36.5%; in their 50s, 20.6%; in their 60s, 15.8%; and in their 80s, 12.6%. Patients had a history of hypertension (46.0%), diabetes (22.2%), stroke (17.4%), lung disease (12.6%), and cancer (11.1%). According to the diagnosis, 48 patients (76.1%) were assigned to the peripheral dizziness group, 7 patients (11.1%) to the central dizziness group, and 8 patients (12.6%) to other dizziness groups. 2) Compared with the peripheral dizziness group, the central dizziness group was older, their history of hypertension 8.4 times greater, their history of stroke 7.8 times greater, and the duration of herbal medicine administration was longer. 3) The vertigo grade was significantly decreased after taking Jeoreongchajeonja-tang (p=0.000). 4) As age increased by one year, odds ratio of improvement in the vertigo grade decreased by 0.924 times after taking Jeoreongchajeonja-tang (p=0.010). 5) Sex, disease duration, past history, diagnosis, the duration of herbal medicine administration, whether or not Yanggyuksanhwa-tang was combined with the Jeoreongchajeonja-tang and whether or not Western medicine was used did not affect improvement in the vertigo grade after taking Jeoreongchajeonja-tang. Conclusions: In patients with dizziness, Jeoreongchajeonja-tang can be used as a treatment without side effects.

• 대한한방내과학회지
• /
• 제40권5호
• /
• pp.948-956
• /
• 2019

Objectives: The purpose of this study was to describe the effectiveness of Jeoreongchajeonja-tang as a treatment for patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Methods: Two irritable bowel syndrome patients who had visited Semyung University Korean Medical Hospital were enrolled. The patients were diagnosed according to the Rome III criteria, and the treatment effect was assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and the colon transit time. Results: After treatment with Jeoreongchajeonja-tang for 4 weeks, the GSRS score was improved and colon transit time was delayed. Conclusions: This study suggests that Jeoreongchajeonja-tang is effective for improving diarrhea-predominant irritable bowel syndrome. More extensive study is needed in the future.

• 사상체질의학회지
• /
• 제30권2호
• /
• pp.8-27
• /
• 2018

Objective This study investigated the effects of Jeoreongchajeonja-tang in a high-fat diet-induced obesity mouse model. Methods The study examined 9-week-old male mice (C57bl/6J) divided into four groups: the normal(C57bl/6J-Nr), control (high-fat diet only; HFD-CTL), positive-control (high-fat diet with Garcinia cambogia), and experimental (high-fat diet with Jeoreongchajeonja-tang; HFD-JCT) groups. After 7 weeks, the body weight, food efficiency ratio, organ weight, and visceral fat weight of the mice were measured. Blood serum tests, mRNA, liver histopathology, and epididymis adipocytes were also examined. Results Compared with the Control(HFD-CTL) group, the Experimental(HFD-JCT) group given Jeoreongchajeonja-tang showed significant reductions in absolute body weight and food efficiency ratio. The serum alanine aminotransferase, total-cholesterol, triglyceride, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, insulin-like growth factor-1, and leptin levels were significantly lower in the experimental group than in the control group. The serum adiponectin levels were significantly higher in the experimental group than in the control group. Compared with the control group, the experimental group showed significant reductions in absolute abdominal subcutaneous fat, epididymal adipose tissue, kidney adipose tissue, intestine adipose tissue, and liver, kidney and spleen adipose tissue weights. The C/EBP-${\beta}$, leptin, and SREBP1c/ADD1 mRNA expression were significantly lower in the experimental group than in the control group, while the UCP-2 and adiponectin mRNA expression were significantly higher. Compared with the control group, the experimental group showed a significant reduction in the absolute adipocyte area in the liver and epididymal adipose tissue. Conclusion Jeoreongchajeonja-tang has an anti-obesity effect. Additional clinical studies are expected.

• 동의신경정신과학회지
• /
• 제23권1호
• /
• pp.145-159
• /
• 2012

Objectives : This research investigates the effect of the JCT extract regarding Alzheimer's disease. Methods : The effects of the JCT extract on IL-$1{\beta}$, IL-6, TNF-${\alpha}$, COX-2, NOS-II mRNA, APP mRNA, BACE mRNA, Nitric oxide(NO), and ${\beta}A$ protein production in the BV2 microglia cell lines treated with LPS and ${\beta}A$ were investigated. Results : 1. The JCT extract suppressed the expression of IL-$1{\beta}$, IL-6, TNF-${\alpha}$, COX-2, and NOS-II mRNA in BV2 microglial cell line treated with LPS and ${\beta}A$. 2. The JCT extract suppressed the expression of BACE and APP mRNA in BV2 microglial cell line treated with LPS and ${\beta}A$. 3. The JCT extract suppressed the expression of Nitric oxide(NO) in BV2 microglial cell line treated with LPS and ${\beta}A$. 4. The JCT extract suppressed the expression of ${\beta}A$ protein production in BV2 microglial cell line treated with LPS and ${\beta}A$. Conclusions : These results suggest that the JCT group may be effective for the treatment of Alzheimer's disease. Thus, JCT could be considered among the future therapeutic drugs indicated for the treatment of Alzheimer's disease.